免疫检查点抑制剂相关心脏毒性的研究进展  

Research Progress on Cardiotoxicity Associated with Immune Checkpoint Inhibitors

作　　者：赵紫薇 胡丽婷 姜馨[2] 

机构地区：[1]西安医学院研究生工作部,陕西 西安 [2]陕西省人民医院心血管内科,陕西 西安

出　　处：《临床医学进展》2023年第10期16772-16778,共7页Advances in Clinical Medicine

摘　　要：免疫检查点抑制剂(ICIs)作为一种新型抗肿瘤药物,在治疗多种恶性肿瘤中取得了前所未有的疗效,极大地改善了肿瘤患者的预后。ICIs激活机体免疫细胞的抗肿瘤作用,同时可导致免疫相关毒性反应,其中,心脏毒性反应虽不常见,但死亡率高、预后差,引起了临床医师的高度关注。本文就ICIs心脏毒性的作用机制、临床表现、诊断方法及治疗进行了综述。As a new type of anti-tumor drugs, immune checkpoint inhibitors (ICIs) have achieved unprece-dented efficacy in the treatment of various malignancies, and greatly improved the prognosis of tumor patients. ICIs activate the anti-tumor effects of immune cells in the body, but they can also lead to immune-related toxic reactions. Although cardiotoxicity is not common, they have high mortality and poor prognosis, which has attracted great attention of clinicians. This article reviews the mechanism, clinical manifestations, diagnosis and treatment of ICIs-related cardiotoxicity.

关 键 词：免疫检查点抑制剂 心脏毒性 心肌炎 肿瘤 

分 类 号：R73[医药卫生—肿瘤]